



NEWS RELEASE

## Insulet Appoints Cristal Downing to Newly Created Role of Chief Corporate Affairs Officer

2025-12-08

ACTON, Mass., December 8, 2025 -- Insulet Corporation (NASDAQ: PODD), the global leader in **tubeless insulin pump technology** with its Omnipod® brand of products, today announced the appointment of Cristal Downing as Chief Corporate Affairs Officer, effective December 8. In this newly created role, Downing will build and lead a top-tier Corporate Affairs function that strengthens Insulet's corporate reputation, advances business priorities, catalyzes customer value, and deepens engagement with the Company's most critical stakeholders. Downing will report to Insulet's President and Chief Executive Officer Ashley McEvoy.

"As Insulet enters its next phase of growth, we have a clear opportunity to more sharply communicate and elevate our transformative story of innovation and impact," said Ms. McEvoy. "Cristal brings deep expertise as a communications and public affairs leader, with a proven ability to shape corporate strategy and navigate complex environments. Her strategic perspective, talent for creating meaningful, human-centered narratives, and dedication to building stakeholder trust will play a critical role in helping us bring Omnipod to even more people globally."

Ms. Downing brings more than 20 years of executive leadership experience at some of the world's most respected companies, where she guided organizations through transformation, high-stakes issues, and major corporate milestones. Most recently, she served as Executive Vice President and Chief Communications & Public Affairs Officer at Merck, leading a global organization of approximately 300 professionals. In this role, she developed and executed strategies that strengthened the company's global reputation, enabled strong business performance, and created long-term stakeholder value.

Prior to Merck, Ms. Downing held senior roles at Johnson & Johnson, including Vice President, Global

Communications & Public Affairs for the Medical Devices business, and Vice President, Financial Communications, partnering with the chief financial officer to reinforce the company's financial narrative and bolster CEO and CFO platforms. She has also held strategic communications roles at American Express, JPMorgan Chase, and Wells Fargo.

At Insulet, Ms. Downing will oversee Global Communications, Public Policy, Government Affairs, and Corporate Reputation & Stakeholder Engagement, serving as a strategic advisor to the CEO and Executive Leadership Team.

"I am honored and excited to join Insulet at such a pivotal moment in its growth trajectory," said Cristal Downing. "Insulet's mission and unwavering commitment to improving the lives of people with diabetes deeply resonate with me. I look forward to partnering with Ashley and the executive team to amplify Insulet's voice, strengthen stakeholder trust, and help shape an operating environment that enables the Company to accelerate innovation, expand global access, and deliver enduring value to Podders, providers and the communities we serve."

#### About Insulet Corporation

Insulet Corporation (NASDAQ: PDD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit [Insulet.com](https://www.insulet.com) or [omnipod.com](https://www.omnipod.com).

#### Investor Relations:

Clare Trachtman

Vice President, Investor Relations

(978) 218-0889

[\*\*ctrachtman@insulet.com\*\*](mailto:ctrachtman@insulet.com)

#### Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com